RPG Life Sciences moves API unit to subsidiary in ₹33.55 crore slump sale
AI Market Summary
RPG Life Sciences approved a slump sale of its API business into a wholly owned subsidiary, alongside external capital injection for ~40% of the subsidiary and a planned acquisition of Actis Generics. The structure appears aimed at ring-fencing the API unit to attract specialized funding and pursue supply-chain integration, without altering the listed entity's shareholding. Near-term market impact is likely localized to Indian pharma risk appetite rather than broader macro assets.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.88%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
RPG Life Sciences is carving out its active pharmaceutical ingredients (API) business into a newly set-up subsidiary, RPGAP, in a transaction valued at ₹33.55 crore. The API unit contributed revenue of ₹95.06 crore in FY26, or 13.54% of consolidated turnover, and had net worth of ₹70.92 crore, or 11.72% of the group total. In a separate disclosure, ILSF and VJF said they will invest a combined ₹243.33 crore in RPGAP for about a 40% stake, while RPGAP also signed an agreement to acquire 100% of bulk drug intermediate supplier Actis Generics.
